What’s new with DiaSorin Molecular.

Available here is a selection of our latest news about DiaSorin Molecular.
Published on 18 Dec 2017

DiaSorin Molecular Launches New Simplexa™ Bordetella Direct Molecular Test

DiaSorin Molecular LLC receives CE Mark for a new Bordetella molecular diagnostic test. Simplexa™ Bordetella Direct is designed to quickly provide qualitative detection and differentiation of both Bordetella pertussis and Bordetella parapertussis in human nasopharyngealswabs.

DiaSorin Molecular
Published on 4 Oct 2017

DiaSorin Molecular Introduces Two Primer Pair Reagents for Streptococcus

DiaSorin Molecular introduces two primer pairs – group C and group G Streptococcus – for use in laboratory-developed molecular tests. These new offerings join DiaSorin’s menu of more than 60 molecular reagents for bacterial, viral and fungal targets in addition to human genetic mutations.

DiaSorin Molecular
Published on 26 Sep 2017

DiaSorin Molecular Introduces Primer Pair Reagent for Pneumocystis jirovecii

DiaSorin Molecular announces the expansion of its menu of molecular reagents with the introduction of a P. jirovecii primer pair for use in laboratory-developed molecular tests. (more…)

DiaSorin Molecular
Published on 21 Sep 2017

Extended CE-IVD Certification Expands Sample Claim for DiaSorin Molecular’s Simplexa HSV 1 & 2 Kit

DiaSorin Molecular, LLC announced today that the company has earned CE-IVD certification extending the sample claims for its Simplexa HSV 1 & 2 Direct Assay. The certification adds – cutaneous and mucocutaneous lesion swabs – to previously cleared specimen types of cerebrospinal fluid (CSF) and genital lesion swabs.

DiaSorin Molecular
Published on 12 Sep 2017

DiaSorin Molecular Receives FDA Clearance for Reliable C. difficile Assay on LIAISON® MDX Platform

DiaSorin Molecular today announced the U.S. introduction of the SimplexaTM C. difficile Direct Assay, upon receiving clearance from the Food and Drug Administration.

The new assay runs on the company’s LIAISON® MDX system, a scalable benchtop PCR instrument that delivers qualitative and quantitative, sample-to-answer, multi-analyte results. The Simplexa assay detects the Clostridium difficile toxin B gene (tcdB), present in liquid or unformed stool samples, aiding in the diagnosis of C. difficile infection.

DiaSorin Molecular
Published on 10 Jul 2017

DiaSorin Molecular launches IAM CBFB-MYH11, completing the diagnostic test menu for molecular screening of acute myeloid leukemia by Q-LAMP.

DiaSorin Molecular launches a new CE-IVD molecular diagnostic test, Iam CBFB-MYH11 (not available in the USA) for the ultra-rapid identification of one of the most common genetic causes of Acute Myeloid Leukemia (AML). This new early diagnosis will aid effective stratification of patient risk, facilitating timely and effective implementation of therapy for patient management improvement.

DiaSorin Molecular


The upcoming events we are going to take part in.

Discover our Events